CLINICAL TRIALS PROFILE FOR PROTONIX

All Clinical Trials for PROTONIX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00133770 ↗	Intravenous (IV) Pantoprazole in Erosive Esophagitis	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 4	2004-07-01	The aim of this study is to examine whether pantoprazole (Protonix) given through continuous intravenous infusion for 72 hours is superior to Protonix given through once a day IV injection in the treatment of erosive esophagitis.
NCT00133770 ↗	Intravenous (IV) Pantoprazole in Erosive Esophagitis	Completed	Emory University	Phase 4	2004-07-01	The aim of this study is to examine whether pantoprazole (Protonix) given through continuous intravenous infusion for 72 hours is superior to Protonix given through once a day IV injection in the treatment of erosive esophagitis.
NCT00206050 ↗	Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po	Completed	AstraZeneca	Phase 4	2004-09-01	This Phase IV study is intended to compare intragastric acid suppression of oral esomeprazole (NEXIUM ® Delayed-Release Capsules) with that of oral pantoprazole (PROTONIX ® Delayed Release Tablets ), in subjects who continue to require acid-suppressive therapy following a course of intravenous (iv) pantoprazole (PROTONIX ® I.V. for Injection).
NCT00625274 ↗	A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients	Completed	AstraZeneca	Phase 4	2004-06-01	This study looks at controlling intragastric pH following administration of esomeprazole 40 mg, lansoprazole 30 mg and pantoprazole 40 mg taken orally, once daily in patients taking either non-selective or cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drugs (NSAIDs).
NCT00674245 ↗	Effect of Pantoprazole 40mg Daily vs Placebo on Power Spectral Analysis of the Sleep EEG of Patients With GERD.	Completed	Southern Arizona VA Health Care System	Phase 2/Phase 3	2008-04-01	The purpose of this research study is to determine if treatment with pantoprazole 40 mg daily versus a placebo improves sleep quality in patients with gastroesophageal reflux disease (GERD). Another purpose is to determine if treatment with pantoprazole 40 mg once daily versus a placebo improves sleep outcomes in patients with gastroesophageal reflux disease using spectral analysis of sleep electroencephalogram (EEG).

Clinical Trial Conditions for PROTONIX

Condition Name

Condition Name for PROTONIX
Intervention	Trials
Healthy	10
Proton Pump Inhibitor Allergy	2
Healthy Adults	2
Esophagitis	2

Condition MeSH

Condition MeSH for PROTONIX
Intervention	Trials
Gastroesophageal Reflux	5
Malnutrition	3
Gastrointestinal Hemorrhage	2
Esophagitis	2

Clinical Trial Locations for PROTONIX

Trials by Country

Trials by Country for PROTONIX
Location	Trials
United States	21
Canada	9
India	6
Saudi Arabia	1
Bosnia and Herzegovina	1

Trials by US State

Trials by US State for PROTONIX
Location	Trials
Missouri	4
Texas	3
Wisconsin	2
California	2
Nebraska	2

Clinical Trial Progress for PROTONIX

Clinical Trial Phase

Clinical Trial Phase for PROTONIX
Clinical Trial Phase	Trials
Phase 4	7
Phase 3	3
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for PROTONIX
Clinical Trial Phase	Trials
Completed	20
Terminated	3
Withdrawn	3

Clinical Trial Sponsors for PROTONIX

Sponsor Name

Sponsor Name for PROTONIX
Sponsor	Trials
Wyeth is now a wholly owned subsidiary of Pfizer	2
Mirati Therapeutics Inc.	2
AstraZeneca	2

Sponsor Type

Sponsor Type for PROTONIX
Sponsor	Trials
Industry	22
Other	20
U.S. Fed	1

Protonix (Pantoprazole) Clinical Trials, Market Analysis, and Forecast

Last updated: February 21, 2026

What is the current status of Protonix clinical trials?

Protonix (pantoprazole) is a proton pump inhibitor (PPI) developed by Pfizer. It is approved for gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome. Pfizer has conducted multiple phase IV and post-marketing studies to evaluate long-term safety, efficacy, and new indications.

Active Clinical Trials (as of 2023)

• Phase IV and Observational Studies
  • Largest ongoing trial: Post-marketing surveillance on long-term PPI safety (NCT03904436).
  • Objective: Assess risks related to chronic use, including bone fractures and renal issues.
  • Enrollment: Approximately 2,000 patients across the U.S. and Europe.
• New Indications Research
  • GERD/Barrett's Esophagus progression monitoring (NCT04557371).
  • Studying Protonix as part of combination therapy for Helicobacter pylori eradication.

Completed Key Trials

• Trials confirming efficacy in erosive esophagitis.
• Safety evaluations supporting FDA labeling.

What is Protonix's current market position?

Market Dynamics

• The global PPI market was valued at $15.2 billion in 2022.
• Pfizer retained approximately 25% market share in 2022, ranking third behind AstraZeneca ("Nexium") and Takeda ("Prevacid").

Competition and Patent Status

• Protonix's US patent expired in August 2019.
• Generic versions entered the market, reducing Protonix's market share.
• Pfizer retains market share through brand loyalty and intravenous formulations used in hospitals.

Revenue and Pricing

Year	Protonix Revenue (USD millions)	Generic competition impact
2020	1,200	Starting decline
2022	980	Significant erosion

Distribution Channels

• Primarily prescribed in hospitals and outpatient clinics.
• Available as oral tablets, IV formulations, and compounded forms.

What is the market forecast for Protonix?

Short-term Projections (2023-2025)

• Market share decline persists due to generics.
• Pfizer focuses on hospital settings with IV formulations.
• Estimated revenues projected to decline at a compound annual growth rate (CAGR) of -5% to -7%.

Long-term Outlook (2026-2030)

• Protonix may maintain a niche in IV formulations and hospital therapy.
• Launching new formulations or combination therapies could stabilize sales.
• Overall PPI market expected to grow at 3-4% CAGR driven by aging populations and chronic GERD management.

Opportunities for Growth

• Potential higher-margin combination therapies for H. pylori.
• Expanding indications to other gastric conditions.
• Strategic partnerships for biosimilar or new formulation development.

Key challenges

• Patent expiration and commoditization.
• Competition from newer PPIs and 2nd-generation drugs.
• Regulatory hurdles in approvals for new indications.

Conclusion

Protonix remains relevant in specific clinical settings, especially hospitals, although its market share diminishes due to generics. Continued clinical research may unlock new uses, while competitive pressures keep revenue forecasts aligned with overall generic PPI trends.

Key Takeaways

• Clinical trials focus on long-term safety and combination therapies, with no significant new indications underway.
• The global PPI market is highly competitive; Protonix's market share has declined since patent expiry.
• Revenue is forecasted to decline 5-7% annually in the short term, with hospital use as a core niche.
• Long-term growth depends on innovation in formulations and expanded indications.
• Pfizer invests in hospital-focused applications to sustain Protonix’s presence.

FAQs

1. Does Protonix have any new clinical trials planned?
No active trials are currently announced that seek new indications beyond existing approved uses.

2. How does Protonix compare with competitors like Nexium?
Protonix is priced competitively in hospital settings and has a broad IV formulation, whereas Nexium (esomeprazole) commands higher outpatient market share due to its slightly different efficacy and brand recognition.

3. What are the main risks for Protonix's market share?
Generic versions replacing branded Protonix significantly impact revenues. The emergence of newer PPIs and alternative therapies also pose risks.

4. What potential does Protonix have in emerging markets?
Growth prospects depend on hospital infrastructure and the prevalence of GERD-related conditions, but market entry is challenged by local generics and price sensitivity.

5. Could Protonix be repositioned for new therapeutic uses?
Potential exists if future clinical trials identify additional effective indications, particularly in combination therapies or specific gastric conditions.

---

References

[1] Pfizer Inc. (2022). Protonix (pantoprazole) product labeling. FDA.
[2] MarketWatch. (2022). Proton Pump Inhibitors Market Size, Share & Trends.
[3] ClinicalTrials.gov. (2023). Ongoing and completed clinical trials involving Protonix.
[4] IQVIA. (2023). Global PPI Market Report.
[5] U.S. Patent and Trademark Office. (2019). Patent expiry date for Protonix.